Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Tessera Therapeutics

Main focus: Gene writing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: Gene writing, mobile genetic elements

Funding stage: Private

Location: Cambridge, MA, USA


Tessera Therapeutics is a Flagship Pioneering founded start-up company that focuses on a novel gene-editing technology known as gene writing. Gene writing is based on using mobile genetic elements to make insertions and deletions, and the technology is being developed to address many of the current limitations of existing gene-editing approaches. While the company has not yet disclosed any of its pre-clinical programmes, it has recently raised $230M in a Series B financing.


HashtagTessera Therapeutics

Company: Tessera Therapeutics
Search CRISPR Medicine